脐带间充质干细胞移植治疗初发1型糖尿病

背景：研究证实，新诊断的1型糖尿病患者，接受自体造血干细胞治疗后，绝大多数患者胰岛β细胞功能增强，不依赖胰岛素的时间也延长。 目的：观察人脐带间充质干细胞移植治疗初发1型糖尿病的临床疗效。 方法：选择12例病程<3个月的初发1型糖尿病患者，其中6例行人脐带间充质干细胞和胰岛素治疗，另外6例行单纯胰岛素治疗。移植前及移植9个月后分别监测空腹及餐后血糖、胰岛素用量、C肽、HbA1c的变化和记录不良反应。 结果与结论：随访9个月，干细胞治疗组的空腹血糖，糖化血红蛋白及C肽水平都有明显的改善，而对照组C肽水平明显下降，其他指标变化不明显。提示，人脐带间充质干细胞治疗初发1型糖尿病疗效良好。

Umbilical cord mesenchymal stem cells transplantation for newly-onset type 1 diabetes

BACKGROUND: Autologous hematopoietic stem cells transplantation can enhance function of beta cells of islet and prolong time independent of insulin. OBJECTIVE: To observe the clinical efficacy of human umbilical cord mesenchymal stem cells (hUCMSCs) transplantation in treatment of newly-onset type 1 diabetes. METHODS: A total of 12 patients with newly-onset type 1 diabetes mellitus (less than 3 months) were selected. Six cases were treated by hUCMSCs transplantation and insulin, and the other 6 were treated by insulin alone. Before and 9 months after transplantation, fasting and postprandial blood glucose, insulin dosage, C peptide, HbA1c changes and adverse events were measured. RESULTS AND CONCLUSION: Patients were followed up for 9 months. Fasting blood glucose, HbA1c and C peptide levels were significantly improved in stem cell therapy group compared with control group. In addition to significantly reduced C peptide levels, other indexes remained unchanged in control group. Results showed that hUCMSCs transplantation has positive effects on treatment of newly-onset type l diabetes.